Search research articles
Contact Us
Filters
Showing results (81-90 of 97) with videos related to
Page
of 10
Sort By:
Transplant International : Official Journal of the European Society for Organ Transplantation
|
May 9, 2022
Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients-A Prospective Study
Dafna Yahav, Ruth Rahamimov, Tiki Mashraki, et al.
ESC Heart Failure
|
January 4, 2022
Six-months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device-supported patients
Osnat Itzhaki Ben Zadok, Aviv A Shaul, Binyamin Ben-Avraham, et al.
Infection
|
November 26, 2024
Shorter vs. standard-duration antibiotic therapy for nocardiosis: a multi-center retrospective cohort study
Nofar Hezkelo Attias, Tal Schlaeffer-Yosef, Itay Zahavi, et al.
Journal of Clinical Medicine
|
August 14, 2025
In Vitro Antimicrobial Activity of the Novel Antimicrobial Peptide OMN51 Against Multi-Drug-Resistant <i>Pseudomonas aeruginosa</i> Isolated from People with Cystic Fibrosis
Moshe Heching, Moshe Cohen-Kutner, Haim Ben-Zvi, et al.
European Journal of Heart Failure
|
May 8, 2021
Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study
Osnat Itzhaki Ben Zadok, Aviv A Shaul, Binyamin Ben-Avraham, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
March 4, 2022
Improved immunogenicity following the third dose of BNT162b2 mRNA vaccine in heart transplant recipients
Aviv Avraham Shaul, Osnat Itzhaki Ben Zadok, Binyamin Ben-Avraham, et al.
Haematologica
|
July 29, 2021
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
Ronit Gurion, Uri Rozovski, Gilad Itchaki, et al.
BMC Infectious Diseases
|
March 1, 2018
Characterization of hepatitis B and delta coinfection in Israel
Rachel Shirazi, Daniela Ram, Aviya Rakovsky, et al.
Vaccines
|
April 28, 2023
Immunogenicity of a Third Dose of BNT162b2 Vaccine among Lung Transplant Recipients-A Prospective Cohort Study
Yael Shostak, Mordechai R Kramer, Omer Edni, et al.
Emerging Infectious Diseases
|
June 22, 2023
Nationwide Outbreak of Candida auris Infections Driven by COVID-19 Hospitalizations, Israel, 2021-2022
Roni Biran, Regev Cohen, Talya Finn, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 97) with videos related to
Sort By:
Page
of 10
Transplant International : Official Journal of the European Society for Organ Transplantation
|
May 9, 2022
Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients-A Prospective Study
Dafna Yahav, Ruth Rahamimov, Tiki Mashraki, et al.
ESC Heart Failure
|
January 4, 2022
Six-months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device-supported patients
Osnat Itzhaki Ben Zadok, Aviv A Shaul, Binyamin Ben-Avraham, et al.
Infection
|
November 26, 2024
Shorter vs. standard-duration antibiotic therapy for nocardiosis: a multi-center retrospective cohort study
Nofar Hezkelo Attias, Tal Schlaeffer-Yosef, Itay Zahavi, et al.
Journal of Clinical Medicine
|
August 14, 2025
In Vitro Antimicrobial Activity of the Novel Antimicrobial Peptide OMN51 Against Multi-Drug-Resistant <i>Pseudomonas aeruginosa</i> Isolated from People with Cystic Fibrosis
Moshe Heching, Moshe Cohen-Kutner, Haim Ben-Zvi, et al.
European Journal of Heart Failure
|
May 8, 2021
Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study
Osnat Itzhaki Ben Zadok, Aviv A Shaul, Binyamin Ben-Avraham, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
March 4, 2022
Improved immunogenicity following the third dose of BNT162b2 mRNA vaccine in heart transplant recipients
Aviv Avraham Shaul, Osnat Itzhaki Ben Zadok, Binyamin Ben-Avraham, et al.
Haematologica
|
July 29, 2021
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
Ronit Gurion, Uri Rozovski, Gilad Itchaki, et al.
BMC Infectious Diseases
|
March 1, 2018
Characterization of hepatitis B and delta coinfection in Israel
Rachel Shirazi, Daniela Ram, Aviya Rakovsky, et al.
Vaccines
|
April 28, 2023
Immunogenicity of a Third Dose of BNT162b2 Vaccine among Lung Transplant Recipients-A Prospective Cohort Study
Yael Shostak, Mordechai R Kramer, Omer Edni, et al.
Emerging Infectious Diseases
|
June 22, 2023
Nationwide Outbreak of Candida auris Infections Driven by COVID-19 Hospitalizations, Israel, 2021-2022
Roni Biran, Regev Cohen, Talya Finn, et al.
Page
of 10